CEO Conference Call/Webcast Scheduled for 5:00 p.m. (EDT)
Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI) announced that at
shortly after 4:00 p.m. (EDT) this...
Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI) today announced that the
Company has filed its Annual Report (Form 10-K) with the SEC, reporting
the results of its operations for...
#12: Biovest Announces It Has Closed an $8.5M Financing to Support Unblinding and Data Analysis of Fast Tracked Pivotal Phase 3 Study of BiovaxID for Non-Hodgkin's Lymphoma with Public Release of Results Anticipated by April 2008
Biovest Announces It Has Closed an $8.5M Financing to Support Unblinding and Data Analysis of Fast Tracked Pivotal Phase 3 Study of BiovaxID for Non-Hodgkin's Lymphoma with Public Release of...
#11: BVTI News U.S. Bank, State of Missouri, and City of St. Louis Partner With Biovest International to Provide Second Round of New Market Tax Credits
WORCESTER, Mass. & ST. LOUIS--(BUSINESS WIRE)--U.S. Bank, the State of Missouri and the City of St. Louis (NYSE:USB)
have provided financing and incentives to help further the development ...
WORCESTER, Mass.--(BUSINESS WIRE)--Biovest International, Inc. (OTCBB:BVTI) announced that it has launched
its breakthrough AutovaxID automated cell culture device for commercial ...
WORCESTER, Mass.--(BUSINESS WIRE)--Biovest International, Inc. (OTCBB: BVTI) announced that a publication
in the September 20th issue of the Journal of the National Cancer
Institute...
WORCESTER, Mass.--(BUSINESS WIRE)--Biovest International, Inc. (OTCBB: BVTI)
has received notification from the Commission of the European Union on
its acceptance of Biovest’s...
#7: BVTI News Biovest International Receives Positive Opinion on Application for Orphan Medicinal Product Designation by European Agency; Opinion expected to aid approval of BiovaxID(TM) in the EU
WORCESTER, Mass.--(BUSINESS WIRE)--July 31, 2006--Biovest International, Inc. (OTCBB: BVTI) has received official notification from the Committee on Orphan Medical Products (COMP) of the European...
WORCESTER, Mass.--(BUSINESS WIRE)--July 26, 2006--Biovest International, Inc. (OTCBB: BVTI) has appointed a new member to its Management team. Christopher Kyriakides, M.D., has been named Senior...
#5: BVTI News Biovest International Gains Key Regulatory Approval for Clinical Trial Sites in Russia; Biovest to open 14 new clinical sites, accelerating patient recruitment
WORCESTER, Mass.--(BUSINESS WIRE)--July 18, 2006--Biovest International, Inc. (OCTBB: BVTI) has received regulatory approval from the Russian Ministry of Health and Social Development of the...
#4: BVTI News Accentia Biopharmaceuticals Announces Option Agreement with Mayo on Patented Treatment Using Intranasal Antifungals for Chronic Sinusitis
TAMPA, Fla.--(BUSINESS WIRE)--Dec. 15, 2005--Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI) announced today that it has signed an option agreement with the Mayo Foundation for Medical Education...
#2: BVTI News AutovaxID(TM)-C Introduced by Biovest International; Automated Instrumentation Marks Major Breakthrough for Vaccine Production and Personalized Medicine
WORCESTER, Mass.--(BUSINESS WIRE)--Dec. 8, 2005--Biovest International, Inc. (OTCBB:BVTI), a biopharmaceutical company focused on the development of patient specific immunotherapeutics and...
#3: BVTI News AutovaxID(TM)-C Introduced by Accentia Biopharmaceuticals; Automated Instrumentation Marks Major Breakthrough for Vaccine Production and Personalized Medicine
TAMPA, Fla.--(BUSINESS WIRE)--Dec. 8, 2005--Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI), announced that its subsidiary, Biovest International, Inc., presented its newest cell culture...
TAMPA, Fla.--(BUSINESS WIRE)--Dec. 6, 2005--Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI) announced today that it has entered into an exclusive license with Collegium Pharmaceuticals, Inc....
